Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: July 2007
-
By Baltazar Gomez — On July 16, 2007, ProMetic BioSciences Inc. and Laboratorios Dermatologicos Darier S.A. announced that the companies had entered into an agreement to develop and market ProMetic’s synthetic anti-inflammatory compound PBI-1308 in dermatological disorders. PBI-1308 is a novel compound with in vivo efficacy in animal models of atopic dermatitis and…
-
By Christopher P. Singer — Given the growing popularity of the USPTO’s web-based electronic filing system (EFS-Web) and the Office’s continuing efforts to improve the system, there has never been a better time to start filing documents with the Patent Office electronically. Many of the initial glitches have been resolved, and the electronic…
-
By Christopher P. Singer — Increase in EP Search Authority Fees In a notice published late last month, the USPTO announced WIPO’s decision to establish higher search fees for searches performed by the European Patent Office, effective on August 1, 2007. On that date the fee the EPO will charge to act as…
-
By Kevin E. Noonan — The Board of Patent Appeals and Interferences recently got its long awaited opportunity to opine on the continued validity of the Federal Circuit’s In re Deuel decision in light of the Supreme Court’s recent decision in KSR Int’l Co. v. Teleflex Inc. Deuel is widely acknowledged (and decried…
-
By Jason Derry — Novocell Inc. recently announced that it has received an additional $25 million in funding from a number of its stakeholders, including Johnson & Johnson Development Corp., Sanderling Ventures, Asset Management Co., and Pacific Horizon Ventures. Novocell is located in San Diego, and focuses on stem cell research. Its primary…
-
By Kevin E. Noonan — There may be some good news with regard to the safety of generic drugs obtained from China. Despite recent evidence that the U.S. Food and Drug Administration has been woefully deficient in inspecting generic drug manufacturers overseas (see "The Effect of Foreign Generics on the U.S. Drug Supply…
-
By Jason Derry — Tikvah Therapeutics, Inc. and Apkarian Technologies, LLC of Chicago have announced an agreement relating to Apkarian’s patents and patent applications involving NMDA receptor agonists. The patents and applications specifically relate to the treatment of chronic pain and pain-related indications using glycine receptor agonists. Under the agreement, Tikvah receives exclusive…
-
By Sherri Oslick — In follow up to our earlier post, Amgen Inc. announced on Monday that it has completed its acquisition of Alantos Pharmaceuticals, providing Amgen with Alantos’s DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes, as well as its matrix metalloproteinases platform for osteoarthritis.
-
By Donald Zuhn — As we reported yesterday, last week the United States Patent and Trademark Office (USPTO) posted 48 submissions it received in response to a solicitation for comments on international patent law harmonization. Among those submitting comments were the Biotechnology Industry Association (BIO) (here), Intellectual Property Owners Association (IPO) (here and…
-
By Kevin E. Noonan — The crisis in global drug pricing that has arisen since the institution of the World Trade Organization (WTO), and in particular with regard to the Doha Declaration (see "The Law of Unintended Consequences Arises in Applying TRIPS to Patented Drug Protection in Developing Countries"), is well-recognized. While the…
Patent Docs 